Co-Authors
This is a "connection" page, showing publications co-authored by JAMES WELSH and FERDINANDOS SKOULIDIS.
Connection Strength
1.214
-
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021 05; 9(5):467-475.
Score: 0.188
-
Author Correction: Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun. 2020 Oct 08; 11(1):5144.
Score: 0.188
-
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020 10; 8(2).
Score: 0.188
-
Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun. 2020 09 24; 11(1):4840.
Score: 0.188
-
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. J Thorac Oncol. 2020 12; 15(12):1919-1927.
Score: 0.187
-
Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol. 2020 02; 15(2):266-273.
Score: 0.175
-
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J Immunother Cancer. 2023 07; 11(7).
Score: 0.057
-
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 06 20; 37(18):1558-1565.
Score: 0.043